trending Market Intelligence /marketintelligence/en/news-insights/trending/8_twfFfSaOdL4MYOLs6PUg2 content esgSubNav
In This List

US FDA seeks more information for Advanced Accelerator's tumor drug application

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


US FDA seeks more information for Advanced Accelerator's tumor drug application

The U.S. FDA seeks additional information relating to Advanced Accelerator Applications SA's new drug application for Lutathera for the treatment of gastroenteropancreatic neuroendocrine tumors.

In a complete response letter, which follows a discipline review letter in November, the agency noted issues with the format, traceability, uniformity and completeness relating to datasets from certain clinical studies that are precluding its reviewers from performing the required independent analysis of the studies.

The letter requests subgroup analyses for gender, age and racial subgroups, as well as other stratification factors and important disease characteristics. A safety update on clinical and nonclinical studies, which is already in process, was also requested.

In addition, the FDA noted in the letter that any observations made during inspections of manufacturing facilities supporting the new drug application need to be resolved before the application's approval.

The agency did not request additional clinical studies, and there were no comments at this time on other sections of the new drug application submission.